William W. Lockwood

University of British Columbia — Canada

Medicine · Health Sciences

48h-index7.4kcitations376works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(80), RNA modifications and cancer(58), Cancer Genomics and Diagnostics(40), Epigenetics and DNA Methylation(22), Japanese History and Culture(21)

Publications376 total

PP01.25/OA04.01: Establishing a System to Elucidate Differences in the Interactomes of Wild Type and Mutant MET Receptors
Journal of Thoracic Oncology·2026
PP01.11: Investigating Mediators of ERK Hyperactivation Mediated Toxicity in Lung Adenocarcinoma
Journal of Thoracic Oncology·2026
Supplementary Tables S1-S8 from Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy
2025Open Access
Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC
Journal of Thoracic Oncology·2025· 6 citedOpen Access
Data from Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy
2025Open Access
Supplementary Figures S1-S10 from Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy
2025Open Access
Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma
Oncogene·2025· 4 citedOpen Access
PP01.02 Potentiating ERK Hyperactivation by Targeting the Proteostasis Network
Journal of Thoracic Oncology·2025
PP01.09 Integrin-Linked Kinase Drives Drug-Tolerant Persister Cell Survival and EMT in Response to EGFR Inhibition in Lung Adenocarcinoma
Journal of Thoracic Oncology·2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy
Cancer Discovery·2025· 10 citedOpen Access
MET Activation in Lung Cancer and Response to Targeted Therapies
Cancers·2025· 6 citedOpen Access
Translation of a longitudinal survey of veterans’ well-being into action by a research-practice-policy partnership
Frontiers in Public Health·2024· 1 citedOpen Access
Extracellular Vesicles from Lung Adenocarcinoma Cells Induce Activation of Different Cancer-Associated Fibroblast Subtypes
Biomedicines·2024· 2 citedOpen Access
P3.03I.07 Comprehensive Pan-Cancer Analysis of Oncogenic MET Rearrangements with a Focus on Targetability in NSCLC
Journal of Thoracic Oncology·2024Open Access
P3.02G.02 Integrin-Linked Kinase Facilitates Drug Tolerant Persister Cell Survival and EMT in Response to EGFR Targeted Therapy
Journal of Thoracic Oncology·2024Open Access
Uncovering molecular features driving lung adenocarcinoma heterogeneity in patients who formerly smoked
Journal of Translational Medicine·2024Open Access
Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response
British Journal of Cancer·2024Open Access
Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia
JTO Clinical and Research Reports·2024· 2 citedOpen Access
Characterizing the secretome of EGFR mutant lung adenocarcinoma
Frontiers in Oncology·2024· 2 citedOpen Access
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC
Journal of Thoracic Oncology·2023· 19 citedOpen Access
page 1 of 19Next →

Frequent Co-authors

Wan L. Lam(28), Adi F. Gazdar(17), Raj Chari(15), Calum MacAulay(12), John D. Minna(10), Kelsie L. Thu(10), Stephen Lam(9), John C. English(8), Emily A. Vucic(7), Stephen Lam(7), Harold Varmus(6), Ming‐Sound Tsao(6), Bradley P. Coe(6), Luc Girard(5), Larissa A. Pikor(5), Hiromasa Yamamoto(4), Junichi Soh(4), Daiana D. Becker‐Santos(4), Kevin L. Bennewith(4), Arun M. Unni(4)